#CovidStocks
Text
The Coronavirus Coping Portfolio (QDEL, GILD, QBIO, CYDY)
The COVID-19 pandemic has forced a dramatic realignment of social, cultural, and economic agendas because, in all cases, the healthcare issue has priority. It’s not a genuine public debate – if you don’t solve the healthcare crisis, you can’t solve any of the other crises that have been boiling over in the public discourse.
That puts a ton of pressure on the vaccine race. But an effective vaccine will take at least another 4-6 months, and probably longer than that. Which brings us to the coping tools: Therapeutics and diagnostics.
For investors, the coping theme is a treasure trove. Companies able to offer real resources to help manage the situation until a viable vaccine candidate is available will reap huge rewards. We profile several stocks on this interesting playing board here: Quidel Corporation (NASDAQ:QDEL), Gilead Sciences, Inc. (NASDAQ:GILD), Q BioMed Inc. (OTCMKTS:QBIO), and CytoDyn Inc (OTCMKTS:CYDY).
Quidel Corporation (NASDAQ:QDEL) leapt onto the stage in spectacular form on Monday after news spread that the FDA approved its antigen testing method following the close of trading last Friday. An effective antigen test is a superior option to the PCR RNA testing we have been leveraging thus far in our fight against the new coronavirus.
The QDEL antigen test is expected to change the game for testing for COVID-19, with results in minutes rather than days. That’s a key part of an effective “test and trace” approach to tracking and defeating this enemy. The stock exploded higher in response to the news, but there may still be room to run.
Quidel Corporation (NASDAQ:QDEL) frames itself as a company that develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide.
It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates.
The stock has been ripping over recent days, up something like 50% in that time.
Quidel Corporation (NASDAQ:QDEL) pulled in sales of $174.7M in its last reported quarterly financials, representing top line growth of 18%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($108.8M against $136.2M, respectively).
Gilead Sciences, Inc. (NASDAQ:GILD) is the leading player in the treatment, or therapeutic, domain when it comes to the pandemic. It’s ebola anti-viral asset, remdesivir, has shown legitimate promise as a weapon against COVID-19, especially when administered early in the disease progression.
That said, the results suggest this isn’t a “silver bullet” drug, and it has to be administered at a hospital, where few “early” patients ever are. But it does work, and evidence mounts that it represents a key part of our response puzzle.
Gilead Sciences, Inc. (NASDAQ:GILD) promulgates itself as a biopharmaceutical company that discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally.
The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging.
In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration.
It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark continuation to the upside.
Gilead Sciences, Inc. (NASDAQ:GILD) generated sales of $5.5B, according to information released in the company's most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of -5.6% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($21B against $8.9B).
Q BioMed Inc. (OTCMKTS:QBIO) is a biomedical acceleration and development company that focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.
The company’s ace offering is Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. Q BioMed Inc. has a research partnership with Mannin Research Inc. for the development of therapeutics to treat a variety of vascular diseases, including the new coronavirus.
In addition, the company is working on adjunct treatments for complications stemming from COVID-19. The main asset under development (rapid path) through the company’s partner, Mannin, is targeting the stabilization of 'leaky vessels' that play a critical part in organ injury, a major determinant of negative outcomes in patients affected by several infectious diseases, including influenza and the current COVID-19 pandemic.
Q BioMed Inc. is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.
The company focuses exclusively in the biotechnology and healthcare sectors, targeting a broad spectrum of biomedical products and healthcare solutions. Q’s expertise is in business & product development and the capital formation required for phased advancement of products.
Q BioMed’s team assists companies by utilizing its strategic partners and network of experts to provide public market access for private company assets. 80% of biomedical start-ups lack capital and resources to transition from incubation to development and beyond.
Q BioMed Inc. (OTCMKTS:QBIO) expects to maximize risk-adjusted returns by focusing on value-driven assets from early stage to near-revenue businesses where the technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.
CytoDyn Inc (OTCMKTS:CYDY) is another treatment play. The company is currently testing the efficacy of its HIV drug, leronlimab. So far, CYDY is actually riding a wave of positive momentum in terms of the direction of this narrative.
As a result, shares of the stock are up as much as 900% in the past 3-4 months.
CytoDyn Inc (OTCMKTS:CYDY) promulgates itself as a late-stage biotechnology company that focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection.
Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease.
CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
And the stock has been acting well over recent days, up something like 12% in that time.
CytoDyn Inc (OTCMKTS:CYDY) had no reported sales in its last quarterly financial data. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($7.1M against $41M, respectively).
Read the full article
0 notes
Text
The Coronavirus Coping Portfolio (QDEL, GILD, QBIO, CYDY)
The COVID-19 pandemic has forced a dramatic realignment of social, cultural, and economic agendas because, in all cases, the healthcare issue has priority. It’s not a genuine public debate – if you don’t solve the healthcare crisis, you can’t solve any of the other crises that have been boiling over in the public discourse.
That puts a ton of pressure on the vaccine race. But an effective vaccine will take at least another 4-6 months, and probably longer than that. Which brings us to the coping tools: Therapeutics and diagnostics.
For investors, the coping theme is a treasure trove. Companies able to offer real resources to help manage the situation until a viable vaccine candidate is available will reap huge rewards. We profile several stocks on this interesting playing board here: Quidel Corporation (NASDAQ:QDEL), Gilead Sciences, Inc. (NASDAQ:GILD), Q BioMed Inc. (OTCMKTS:QBIO), and CytoDyn Inc (OTCMKTS:CYDY).
Quidel Corporation (NASDAQ:QDEL) leapt onto the stage in spectacular form on Monday after news spread that the FDA approved its antigen testing method following the close of trading last Friday. An effective antigen test is a superior option to the PCR RNA testing we have been leveraging thus far in our fight against the new coronavirus.
The QDEL antigen test is expected to change the game for testing for COVID-19, with results in minutes rather than days. That’s a key part of an effective “test and trace” approach to tracking and defeating this enemy. The stock exploded higher in response to the news, but there may still be room to run.
Quidel Corporation (NASDAQ:QDEL) frames itself as a company that develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide.
It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates.
The stock has been ripping over recent days, up something like 50% in that time.
Quidel Corporation (NASDAQ:QDEL) pulled in sales of $174.7M in its last reported quarterly financials, representing top line growth of 18%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($108.8M against $136.2M, respectively).
Gilead Sciences, Inc. (NASDAQ:GILD) is the leading player in the treatment, or therapeutic, domain when it comes to the pandemic. It’s ebola anti-viral asset, remdesivir, has shown legitimate promise as a weapon against COVID-19, especially when administered early in the disease progression.
That said, the results suggest this isn’t a “silver bullet” drug, and it has to be administered at a hospital, where few “early” patients ever are. But it does work, and evidence mounts that it represents a key part of our response puzzle.
Gilead Sciences, Inc. (NASDAQ:GILD) promulgates itself as a biopharmaceutical company that discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally.
The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging.
In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration.
It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark continuation to the upside.
Gilead Sciences, Inc. (NASDAQ:GILD) generated sales of $5.5B, according to information released in the company's most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of -5.6% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($21B against $8.9B).
Q BioMed Inc. (OTCMKTS:QBIO) is a biomedical acceleration and development company that focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.
The company’s ace offering is Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. Q BioMed Inc. has a research partnership with Mannin Research Inc. for the development of therapeutics to treat a variety of vascular diseases, including the new coronavirus.
In addition, the company is working on adjunct treatments for complications stemming from COVID-19. The main asset under development (rapid path) through the company’s partner, Mannin, is targeting the stabilization of 'leaky vessels' that play a critical part in organ injury, a major determinant of negative outcomes in patients affected by several infectious diseases, including influenza and the current COVID-19 pandemic.
Q BioMed Inc. is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.
The company focuses exclusively in the biotechnology and healthcare sectors, targeting a broad spectrum of biomedical products and healthcare solutions. Q’s expertise is in business & product development and the capital formation required for phased advancement of products.
Q BioMed’s team assists companies by utilizing its strategic partners and network of experts to provide public market access for private company assets. 80% of biomedical start-ups lack capital and resources to transition from incubation to development and beyond.
Q BioMed Inc. (OTCMKTS:QBIO) expects to maximize risk-adjusted returns by focusing on value-driven assets from early stage to near-revenue businesses where the technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.
CytoDyn Inc (OTCMKTS:CYDY) is another treatment play. The company is currently testing the efficacy of its HIV drug, leronlimab. So far, CYDY is actually riding a wave of positive momentum in terms of the direction of this narrative.
As a result, shares of the stock are up as much as 900% in the past 3-4 months.
CytoDyn Inc (OTCMKTS:CYDY) promulgates itself as a late-stage biotechnology company that focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection.
Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease.
CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
And the stock has been acting well over recent days, up something like 12% in that time.
CytoDyn Inc (OTCMKTS:CYDY) had no reported sales in its last quarterly financial data. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($7.1M against $41M, respectively).
Read the full article
0 notes
Text
The Coronavirus Coping Portfolio (QDEL, GILD, QBIO, CYDY)
The COVID-19 pandemic has forced a dramatic realignment of social, cultural, and economic agendas because, in all cases, the healthcare issue has priority. It’s not a genuine public debate – if you don’t solve the healthcare crisis, you can’t solve any of the other crises that have been boiling over in the public discourse.
That puts a ton of pressure on the vaccine race. But an effective vaccine will take at least another 4-6 months, and probably longer than that. Which brings us to the coping tools: Therapeutics and diagnostics.
For investors, the coping theme is a treasure trove. Companies able to offer real resources to help manage the situation until a viable vaccine candidate is available will reap huge rewards. We profile several stocks on this interesting playing board here: Quidel Corporation (NASDAQ:QDEL), Gilead Sciences, Inc. (NASDAQ:GILD), Q BioMed Inc. (OTCMKTS:QBIO), and CytoDyn Inc (OTCMKTS:CYDY).
Quidel Corporation (NASDAQ:QDEL) leapt onto the stage in spectacular form on Monday after news spread that the FDA approved its antigen testing method following the close of trading last Friday. An effective antigen test is a superior option to the PCR RNA testing we have been leveraging thus far in our fight against the new coronavirus.
The QDEL antigen test is expected to change the game for testing for COVID-19, with results in minutes rather than days. That’s a key part of an effective “test and trace” approach to tracking and defeating this enemy. The stock exploded higher in response to the news, but there may still be room to run.
Quidel Corporation (NASDAQ:QDEL) frames itself as a company that develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide.
It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates.
The stock has been ripping over recent days, up something like 50% in that time.
Quidel Corporation (NASDAQ:QDEL) pulled in sales of $174.7M in its last reported quarterly financials, representing top line growth of 18%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($108.8M against $136.2M, respectively).
Gilead Sciences, Inc. (NASDAQ:GILD) is the leading player in the treatment, or therapeutic, domain when it comes to the pandemic. It’s ebola anti-viral asset, remdesivir, has shown legitimate promise as a weapon against COVID-19, especially when administered early in the disease progression.
That said, the results suggest this isn’t a “silver bullet” drug, and it has to be administered at a hospital, where few “early” patients ever are. But it does work, and evidence mounts that it represents a key part of our response puzzle.
Gilead Sciences, Inc. (NASDAQ:GILD) promulgates itself as a biopharmaceutical company that discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally.
The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging.
In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration.
It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark continuation to the upside.
Gilead Sciences, Inc. (NASDAQ:GILD) generated sales of $5.5B, according to information released in the company's most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of -5.6% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($21B against $8.9B).
Q BioMed Inc. (OTCMKTS:QBIO) is a biomedical acceleration and development company that focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.
The company’s ace offering is Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. Q BioMed Inc. has a research partnership with Mannin Research Inc. for the development of therapeutics to treat a variety of vascular diseases, including the new coronavirus.
In addition, the company is working on adjunct treatments for complications stemming from COVID-19. The main asset under development (rapid path) through the company’s partner, Mannin, is targeting the stabilization of 'leaky vessels' that play a critical part in organ injury, a major determinant of negative outcomes in patients affected by several infectious diseases, including influenza and the current COVID-19 pandemic.
Q BioMed Inc. is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.
The company focuses exclusively in the biotechnology and healthcare sectors, targeting a broad spectrum of biomedical products and healthcare solutions. Q’s expertise is in business & product development and the capital formation required for phased advancement of products.
Q BioMed’s team assists companies by utilizing its strategic partners and network of experts to provide public market access for private company assets. 80% of biomedical start-ups lack capital and resources to transition from incubation to development and beyond.
Q BioMed Inc. (OTCMKTS:QBIO) expects to maximize risk-adjusted returns by focusing on value-driven assets from early stage to near-revenue businesses where the technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.
CytoDyn Inc (OTCMKTS:CYDY) is another treatment play. The company is currently testing the efficacy of its HIV drug, leronlimab. So far, CYDY is actually riding a wave of positive momentum in terms of the direction of this narrative.
As a result, shares of the stock are up as much as 900% in the past 3-4 months.
CytoDyn Inc (OTCMKTS:CYDY) promulgates itself as a late-stage biotechnology company that focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection.
Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease.
CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
And the stock has been acting well over recent days, up something like 12% in that time.
CytoDyn Inc (OTCMKTS:CYDY) had no reported sales in its last quarterly financial data. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($7.1M against $41M, respectively).
Read the full article
0 notes
Text
Stocks to Watch Ahead of the “Twindemic” (APT, LAKE, ALST, DGX)
The pandemic is old news. Scientists and health policy experts are now worried about the rising potential for the “Twindemic” – a coincident crisis involving Covid-19 and influenza primed for emergence this fall as people worry about going to the doctor to get their flu shot.
Without widespread adoption of flu shots, the flu could be much worse. If that happens, our already compromised immune systems will be sitting ducks for the much-feared “second wave” jump in Covid-19 cases possible this fall.
For many people, the only obvious strategy may be more effective personal protection equipment and widespread testing.
With that in mind, we look at several stocks primed for potential as markets adjust to the twindemic scenario, including: Alpha Pro Tech, Ltd. (NYSE:APT), Lakeland Industries, Inc. (NASDAQ:LAKE), Allstar Health Brands Inc (OTCMKTS:ALST), and Quest Diagnostics Inc (NYSE:DGX).
Alpha Pro Tech Ltd (NYSE:APT) engages in developing, manufacturing, and marketing a line of disposable protective apparel, building supply products, and infection control products in the United States and internationally. The big idea powering the stock lately is its products of masks capable of helping to prevent the spread of COVID-19.
The company operates through three segments: Building Supply, Disposable Protective Apparel, and Infection Control. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force.
Alpha Pro Tech Ltd (NYSE:APT) announced financial results for the three month period ended June 30, 2020.
Lloyd Hoffman, President and Chief Executive Officer of Alpha Pro Tech, commented, “Alpha Pro Tech delivered another exceptional quarter with triple-digit organic revenue growth, a 123% increase compared to the second quarter of 2019. Gross profit margin was nearly 50%, which is above our historical average, due to a shift in product mix towards more personal protective equipment (PPE) and extremely strong cash flow. As a result of the ongoing COVID-19 pandemic, demand for our N-95 face masks and other PPE remains strong and shows no indications of slowing as we move into the second half of 2020. Our backlog of orders continues to increase with current delivery commitments into the second quarter of 2021.”
The stock has suffered a bit of late, with shares of APT taking a hit in recent action, down about -7% over the past week.
Alpha Pro Tech Ltd (NYSE:APT) managed to rope in revenues totaling $25.5M in overall sales during the company's most recently reported quarterly financial data -- a figure that represents a rate of top line growth of 123.4%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($25M against $11.7M).
Lakeland Industries Inc (NASDAQ:LAKE) bills itself as a company that manufactures and sells industrial protective clothing and accessories for the industrial and public protective clothing market worldwide. It offers limited use/disposable protective clothing, such as coveralls, laboratory coats, shirts, pants, hoods, aprons, sleeves, arm guards, caps, and smocks; high-end chemical protective suits to provide protection from highly concentrated, toxic and/or lethal chemicals, and biological toxins; and firefighting and heat protective apparel to protect against fire, burns, and excessive heat.
The company also provides reusable woven garments, including electrostatic dissipative apparel for electric and gas utilities; flame resistant meta aramid, para aramid, and FR cotton coveralls/pants/jackets used in petrochemical and refining operations; FR fabrics; and cotton and polycotton coveralls, lab coats, pants, and shirts. In addition, it provides high visibility clothing comprising reflective apparel, including vests, T-shirts, sweatshirts, jackets, coats, raingear, jumpsuits, hats, and gloves; and gloves and sleeves that are used in the automotive, glass, and metal fabrication industries.
Lakeland Industries Inc (NASDAQ:LAKE) just recently announced that it has established a new credit facility with Bank of America.
According to the release, the new facility consists of a senior secured $12.5 million revolving credit facility, which includes a $5 million letter of credit sub-facility and an option to convert up to $5 million of the revolving credit facility into a term loan facility. The facility also includes an accordion feature under which the Company may request from time to time an increase in the revolving commitment of up to $5 million (for a total commitment of up to $17.5 million). The facility will mature on June 25, 2025. Terms of the new facility are more completely discussed in the Company's Form 8-K filed with the Securities and Exchange Commission.
The context for this announcement is a bit of a bid, with shares acting well over the past five days, up about 6% in that timeframe. LAKE shares have been relatively flat over the past month of action, with very little net movement during that period.
Lakeland Industries Inc (NASDAQ:LAKE) managed to rope in revenues totaling $45.6M in overall sales during the company's most recently reported quarterly financial data -- a figure that represents a rate of top line growth of 84.7%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($23.5M against $12.9M).
Allstar Health Brands Inc (OTCMKTS:ALST) is dedicated to improving health and quality of life by offering select products, including medical devices, nutritional supplements, over the counter remedies and medicines across the Americas and Europe.
AllStar's goal is to bring additional products to the market and provide new, innovative options for better health and well-being. In addition, according to recent materials, the company has begun to focus sharply on front-line products. AllStar is now working with qualified overseas suppliers to provide products such as PPE (Personal Protective Equipment) as demand is expected to increase sharply with the gradual re-opening of the economy.
Allstar Health Brands Inc (OTCMKTS:ALST) also just recently announced the signing of a new distribution agreement for Mexico and other Latin American countries through TPT Global Tech's partner New Orbit Technologies.
Dr. Daniel Bagi, President of AllStar, observed," Given the increasing Covid-19 infection rates around the world, especially in Mexico, Peru and other Latin American countries and the ability to set up the QuikLAB testing modules at almost any location, we believe countries like Mexico will avail themselves of this testing option. The QuikLab modules can be set up outside malls, at mining sites or other remote locations, and are accessed as drive-up testing. They offer a fast, complete testing option, at a rapid throughput, - up to 50 tests/hour, using either the viral or antibody tests currently available on the market. The goal is to provide results the same day, so appropriate treatment or isolations protocols can be put in place based on the results of the testing."
According to the release, AllStar will provide FDA EUA rapid Covid-19 anti-body tests in concert with TPT Medtech QuikLab solutions to promote the best in class mobile testing solutions throughout Latin America. This innovative solution, including supply chain utilizing testing suppliers globally and North America, ensures a steady supply chain able to meet demand as infections surge across different locations.
Allstar Health Brands Inc (OTCMKTS:ALST) has limited cash on the books against some more significant obligations. ALST is pulling in trailing 12-month revenues. While this is the more speculative name in this group, the company’s engagement in the PPE and antibody testing space as virus numbers continue to ramp across the US should put ALST on a lot of radars.
Quest Diagnostics Inc (NYSE:DGX) promulgates itself as a company that provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.
This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals.
Quest Diagnostics Inc (NYSE:DGX) recently announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to use specimen pooling with its proprietary molecular diagnostic test for COVID-19.
Quest is the first lab provider to receive FDA authorization for the technique for COVID-19 testing in the United States.
It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark things.
Quest Diagnostics Inc (NYSE:DGX) pulled in sales of $1.8B in its last reported quarterly financials, representing top line growth of -6.5%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($988M against $1.8B, respectively).
Read the full article
0 notes
Text
The New Pharmacy Trade (CERN, MDRX, RXMD, RAD)
The stock market may be a bubble at this point, and investors may need to look for countercyclical or noncyclical stocks to own to weather a pullback without losing ground – and maybe taking advantage of some fresh momentum that could come from that rotation process.
One of the most interesting areas of the market for such a positioning strategy could be the pharmacy services space, where one has access to a lack of cyclicality while also benefitting from growth in services arising from increasing technology integration (think: telehealth and telemedicine) and a key role in the battle against COVID-19.
With that said, here are some of the most interesting names in the space: Cerner Corporation (NASDAQ:CERN), Allscripts Healthcare Solutions Inc (NASDAQ:MDRX), Progressive Care Inc. (OTCMKTS:RXMD), and Rite Aid Corporation (NYSE:RAD).
Cerner Corporation (NASDAQ:CERN) frames itself as a company that provides health care information technology solutions and tech-enabled services in the United States and internationally. The company offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers.
It also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, the company offers a portfolio of clinical and financial health care information technology solutions, as well as departmental, connectivity, population health, and care coordination solutions. Further, it provides tech-enabled services, such as implementation and training, remote hosting, operational management services, revenue cycle services, support and maintenance, health care data analysis, clinical process optimization, transaction processing, employer health centers, employee wellness programs, and third-party administrator services; and complementary hardware and devices for third parties.
Cerner Corporation (NASDAQ:CERN) recently announced that Jerome Labat has joined the company as Chief Technology Officer (CTO).
With more than 30 years’ experience in technology and product development leadership at other global Fortune 500 companies, including Hewlett Packard Enterprise Co. (HPE) and Oracle, Labat brings extensive experience in cloud automation, product portfolio strategy, Software-as-a-Service (SaaS) deployment and other critical engineering expertise that are well aligned with Cerner’s technology strategy.
It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark things. Shares of the stock have powered higher over the past month, rallying roughly 5% in that time on strong overall action.
Cerner Corporation (NASDAQ:CERN) managed to rope in revenues totaling $1.4B in overall sales during the company's most recently reported quarterly financial data -- a figure that represents a rate of top line growth of 1.6%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($398.8M against $1B, respectively).
Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) bills itself as a company that provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. The company also just announced a new deal with MSFT that we will cover below.
MDRX offers electronic health records (EHR), connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions. The company operates in two segments, Clinical and Financial Solutions and Population Health.
Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) just put out a release noting that the company and its clients have taken significant actions to ensure effective care delivery in the communities they serve. With unwavering dedication to patient health, caregivers from both large hospital systems and independent physician practices around the world continue to excel in the face of the unprecedented crisis to help manage their patients and combat the spread of the virus.
New York State’s largest health system and longtime Allscripts partner, Northwell Health, was at the epicenter of the outbreak in its initial stages. The system is powered by more than 72,000 clinicians and administrators, and many of its facilities use the Sunrise electronic health record to treat patients and analyze data to identify trends to help improve patient outcomes amidst the pandemic.
It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark things. Shares of the stock have powered higher over the past month, rallying roughly 8% in that time on strong overall action.
Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) generated sales of $416.7M, according to information released in the company's most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of -7.6% on the top line. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($212.1M against $1.2B, respectively).
Progressive Care Inc (OTCMKTS:RXMD) is “a personalized healthcare services and technology company”. It operates a number of pharmacies under the PharmCo RX brand and has an integrated technology, data analytics, testing, and patient management system, along with ecommerce and same-day delivery of prescriptions and products.
The company has been benefitting from a surge in demand for its rapid-results antibody test kits (COVID-19 IgG/IgM) registered through the FDA under its Emergency Use Authorization guidelines for conducting SARS-CoV-2 antibody presence and COVID-19 infection diagnosis testing.
The company has put up impressive numbers, with consolidated monthly gross sales across all locations during May totaling $3 million, representing year-over-year growth of 67%. It was 54% the month before, and 105% in March. And it was even better before the pandemic hit.
Progressive Care Inc (OTCMKTS:RXMD) has been working towards integrating a strong technology services model to bring more scalability into the picture ahead of a coming uplist onto the Nasdaq exchange. As a case in point, the company just announced the launch of “ClearMetrX”, the Company’s first wholly-owned data analytics company with services designed to support health care organizations across the country.
The idea to consolidate data analytics and reporting services in a separate, wholly owned subsidiary of the Company is based on the Company’s evaluation of the data analytics and reporting tools in current pharmacy operations. Over the past 9 months, the Company has generated over $250,000 in data management fees with gross margins exceeding 80%. By creating a separate entity for these services, the programs can be delivered nationwide without the competitive pressures associated with pharmacy. The new subsidiary will focus on providing insights, data security, and technological development. The Company plans to transition data service customers from the pharmacies to the ClearMetrX platform to better scale the products and improve the capabilities of existing analytics options.
If you're long this stock, then you're liking how the stock has responded to the announcement. RXMD shares have been moving higher over the past week overall, pushing about 18% to the upside on above average trading volume.
Progressive Care Inc (OTCMKTS:RXMD) generated sales of $9.1M, according to information released in the company's most recent quarterly financial report. That adds up to a monthly year-over-year growth rate of 62% on the top line as of the Company’s last monthly performance update.
Rite Aid Corporation (NYSE:RAD) operates a chain of retail drugstores in the United States. The company operates through two segments, Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment sells prescription drugs and an assortment of other merchandise, including over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other every day and convenience products.
It also operates retail clinics that provide treatment for common conditions; and provides preventative services, such as screenings, medical tests, immunizations, and basic physical exams. In addition, this segment offers healthcare coaching and disease management services. The Pharmacy Services segment provides pharmacy benefit management (PBM) services and a range of pharmacy-related services. This segment also performs prescription adjudication services for other PBMs; and offers integrated mail-order and specialty pharmacy services, as well as drug benefits under the federal government's Medicare Part D program.
Rite Aid Corporation (NYSE:RAD) continues to follow CDC guidance to ensure safety of customers and associates With COVID-19 cases rising and the Centers for Disease Control and Prevention (CDC) urging widespread adoption of face coverings, Rite Aid will require customers to wear face coverings in all locations effective Tuesday, July 21.
If a customer does not have a face covering, Rite Aid will provide one free of charge.
Even in light of this news, RAD has had a rough past week of trading action, with shares sinking something like -5% in that time. That said, chart support is nearby and we may be in the process of constructing a nice setup for some movement back the other way. Shares of the stock have powered higher over the past month, rallying roughly 21% in that time on strong overall action.
Rite Aid Corporation (NYSE:RAD) pulled in sales of $6B in its last reported quarterly financials, representing top line growth of 12.2%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($288.3M against $2.6B, respectively).
Read the full article
0 notes
Text
Investing in the Age of Covid-19 (LAKE, DGX, ALST, HON)
It has been a roller coaster. In March, the sky was falling. In May, the sun was starting to come back out. It brightened further in June. But July has been so bad even Trump is wearing a mask.
We will get through this. At this point, one might suggest that investors can be smart while making a positive contribution by seeking out opportunities in the capital markets that help fund companies working to provide necessary resources for coping, surviving and even thriving during the dark days ahead.
With that in mind, we take a look at some of the more interesting stocks aligned with this theme, including: Lakeland Industries, Inc. (NASDAQ:LAKE), Quest Diagnostics Inc (NYSE:DGX), Allstar Health Brands Inc (OTCMKTS:ALST), and Honeywell International Inc. (NYSE:HON).
Lakeland Industries, Inc. (NASDAQ:LAKE) bills itself as a company that manufactures and sells industrial protective clothing and accessories for the industrial and public protective clothing market worldwide.
It offers limited use/disposable protective clothing, such as coveralls, laboratory coats, shirts, pants, hoods, aprons, sleeves, arm guards, caps, and smocks; high-end chemical protective suits to provide protection from highly concentrated, toxic and/or lethal chemicals, and biological toxins; and firefighting and heat protective apparel to protect against fire, burns, and excessive heat.
Lakeland Industries, Inc. (NASDAQ:LAKE) just announced that it has established a new credit facility with Bank of America. The new facility consists of a senior secured $12.5 million revolving credit facility, which includes a $5 million letter of credit sub-facility and an option to convert up to $5 million of the revolving credit facility into a term loan facility.
According to the release, the facility also includes an accordion feature under which the Company may request from time to time an increase in the revolving commitment of up to $5 million (for a total commitment of up to $17.5 million). The facility will mature on June 25, 2025. Terms of the new facility are more completely discussed in the Company's Form 8-K filed with the Securities and Exchange Commission.
It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark things. Shares of the stock have powered higher over the past month, rallying roughly 5% in that time on strong overall action.
Lakeland Industries, Inc. (NASDAQ:LAKE) generated sales of $45.6M, according to information released in the company's most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 61.7% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($23.5M against $12.9M).
Quest Diagnostics Inc (NYSE:DGX) promulgates itself as a company that provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.
This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals.
Quest Diagnostics Inc (NYSE:DGX) just announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to use specimen pooling with its proprietary molecular diagnostic test for COVID-19.
Quest is the first lab provider to receive FDA authorization for the technique for COVID-19 testing in the United States.
It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark things. Shares of the stock have powered higher over the past month, rallying roughly 22% in that time on strong overall action.
Quest Diagnostics Inc (NYSE:DGX) pulled in sales of $1.8B in its last reported quarterly financials, representing top line growth of -3.6%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($342M against $1.1B, respectively).
Allstar Health Brands Inc (OTCMKTS:ALST) is dedicated to improving health and quality of life by offering select products, including medical devices, nutritional supplements, over the counter remedies and medicines across the Americas and Europe.
AllStar's goal is to bring additional products to the market and provide new, innovative options for better health and well-being. In addition, according to recent materials, the company has begun to focus sharply on front-line products. AllStar is now working with qualified overseas suppliers to provide products such as PPE (Personal Protective Equipment) as demand is expected to increase sharply with the gradual re-opening of the economy.
Allstar Health Brands Inc (OTCMKTS:ALST) also just recently announced that through one of its network of Distributors has obtained a Covid-19 Rapid Antibody Test Import Permit for Peru. Demand for these types of test kits is expected to increase sharply with the high number of coronavirus infections in Latin America.
Dr. Daniel Bagi, President of AllStar stated," The global pandemic has affected Latin America more recently relative to other countries and especially hard, with many countries in the region overwhelmed by both the infection and death rates. We have been working with our distributors to obtain Import Permits in several countries in South America hardest hit by the pandemic, and our first success is in Peru. The Import Permit is the first step towards sales, and we have already discussed volumes and pricing and expect sales to begin in the next few weeks."
Allstar Health Brands Inc (OTCMKTS:ALST) has limited cash on the books against some more significant obligations. ALST is pulling in trailing 12-month revenues. While this is the more speculative name in this group, the company’s engagement in the PPE and antibody testing space as virus numbers continue to ramp across the US should put ALST on a lot of radars.
Honeywell International Inc. (NYSE:HON) trumpets itself as a company that operates as a diversified technology and manufacturing company worldwide.
The company's Safety and Productivity Solutions segment provides personal protection equipment, apparel, gear, and footwear; gas detection technology; and cloud-based notification and emergency messaging; and mobile devices and software; supply chain and warehouse automation equipment, and software and solutions; custom-engineered sensors, switches, and controls; and software-based data and asset management productivity solutions.
Honeywell International Inc. (NYSE:HON) just released a report based on cybersecurity threat data collected from hundreds of industrial facilities globally showing that the severity of threats detected to operational technology (OT) systems has risen by significant amounts over a 12-month period.
The findings from the latest Honeywell Industrial USB Threat Report show that the total amount of threats posed by USB removable media to industrial process control networks remains consistently high, with 45% of locations detecting at least one inbound threat. Over the same time period, the number of threats specifically targeting OT systems nearly doubled from 16 to 28%, while the number of threats capable of causing a loss of view or other major disruption to OT systems more than doubled, from 26 to 59%.
It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark things.
Honeywell International Inc. (NYSE:HON) managed to rope in revenues totaling $8.5B in overall sales during the company's most recently reported quarterly financial data -- a figure that represents a rate of top line growth of -4.7%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($8.8B against $17.4B, respectively).
Read the full article
0 notes
Last Seen Blogs
imagines-for-teens
I M A G I N E S
worldulastuna
Sarılar en güzeli 😍
directorsclub
directorclub millionaireceoclub.com
autemka
Giggle Fox